share_log

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Needham重申买入Trevi Therapeutics,维持8美元的目标股价
Benzinga ·  05/08 09:27

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发